Nachiappan Chidambaram, Salt Lake City, UT (US); Satish K. Nachaegari, Salt Lake City, UT (US); Mahesh V. Patel, Salt Lake City, UT (US); and Kilyoung Kim, Salt Lake City, UT (US)
Filed by Lipocine, Inc., Salt Lake City, UT (US)
Filed on Nov. 6, 2024, as Appl. No. 18/938,942.
Application 18/938,942 is a continuation of application No. 18/641,597, filed on Apr. 22, 2024, granted, now 12,161,651.
Application 18/641,597 is a continuation of application No. 18/310,784, filed on May 2, 2023, granted, now 11,992,496, issued on May 28, 2024.
Application 18/310,784 is a continuation of application No. 17/132,167, filed on Dec. 23, 2020, granted, now 11,672,807, issued on Jun. 13, 2023.
Application 17/132,167 is a continuation of application No. 16/727,737, filed on Dec. 26, 2019, granted, now 10,881,670, issued on Jan. 5, 2021.
Application 16/727,737 is a continuation of application No. 15/828,320, filed on Nov. 30, 2017, abandoned.
Claims priority of provisional application 62/428,317, filed on Nov. 30, 2016.
Claims priority of provisional application 62/428,167, filed on Nov. 30, 2016.
1. A method of treating a subject having a condition associated with at least one of depression, insomnia, obesity, fatigue, a reduction in muscle size, a reduction in muscle mass, a reduction in muscle strength, a reduction in endurance, reduction in bone size, a reduction in bone mass, and a reduction in bone density, said method comprising orally administering a therapeutically effective amount of pharmaceutical composition (PC) comprising a non-undecanoate testosterone ester in an untitrated dose administration regimen.